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Abstract
Introduction—Care of individuals with Alzheimer’s Disease and Related Dementias (ADRD)
poses special challenges. As the disease progresses, individuals with ADRD require increasing
levels of medical care, caregiver support, and long-term care which can lead to substantial
economic burden.
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Areas covered—In this expert review, we synthesized findings from studies of costs of ADRD
in the United States that were published between January 2006 and February 2017, highlighted
major sources of variation in costs, identified knowledge gaps and briefly outlined directions for
future research and implications for policy and program planning.
Expert commentary—A consistent finding of all studies comparing individuals with and
without ADRD is that the average medical, non-medical, and indirect costs of individuals with
ADRD are higher than those without ADRD, despite the differences in the methods of identifying
ADRD, duration of the study, payer type and settings of study population. The economic burden of
ADRD may be underestimated because many components such as direct non-medical costs for
home safety modifications and adult day care services and indirect costs due to the adverse impact
of ADRD on caregivers’ health and productivity are not included in cost estimates.
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1. Introduction

Author Manuscript

Dementia is an umbrella term used to describe a level of neurocognitive impairment that can
affect a person’s activities of daily living. Multiple etiologies, including Alzheimer’s disease
(AD), vascular disease, presence of Lewy bodies, frontotemporal disease, and brain injury,
can lead to dementia. Alzheimer’s disease and related dementias (ADRD) are generally
characterized by progressive loss of memory and cognitive functioning; functional
impairment in the performance of daily activities such as eating, making meals, bathing, and
paying bills; and manifestation of neuropsychological symptoms such as depression,
anxiety, agitation, apathy, delirium, and psychosis [1]. The most common cause of dementia
among adults aged 65 years and older is AD that accounts for 60–80% of all dementias [2].
Other, less common forms of dementia are vascular dementia (VD), frontotemporal
dementia (FTD), and Lewy body dementia (LBD) that comprise approximately 10%, 10%,
and 4% of dementia cases, respectively [2,3]. It is expected that demographic shifts in the
United States due to the rapid growth of the elderly population will increase the number of
individuals afflicted with AD by threefold in the next 30 years [4].

Author Manuscript

As the disease progresses, individuals with ADRD require increasing levels of care and
support, including medical treatment, prescription drugs, medical equipment, home safety
modifications, safety services, personal care, adult day care, and, ultimately, full-time
residential services. Currently, there is no cure for ADRD, and effective disease-modifying
treatments remain elusive. Therefore, ADRD can impose a high financial burden on payers,
patients and their families, health-care delivery systems, and society as a whole. According
to recent estimates from the Alzheimer’s Association, the total direct medical expenditures
associated with ADRD in the United States will increase from $236 billion in 2016 to more
than $1 trillion in 2050 due to projected increases in the elderly population [2]. These figures
do not take into account informal care and other indirect costs, including the unpaid care
needed for those with ADRD and currently provided by almost 16 million Americans. For
example, in 2015, unpaid caregivers provided approximately 18.1 billion hours of assistance,
and this care has been valued conservatively at $221.3 billion [2].

Author Manuscript

With the rising economic burden of ADRD in the United States, it is important for health
policy planners and other decision makers to gain a comprehensive understanding of the
economic burden of AD/ADRD in the US population. In recent years, several studies have
assessed the direct and indirect cost associated with ADRD [5–19]. Most studies have
differed considerably in their definitions (AD/ADRD), data sources, cost estimation
approaches, components of costs, and the stage at which costs were captured. A rigorous
review and synthesis of studies that include both direct and indirect costs of AD/ADRD in
the US population is lacking. In this critical review, we describe the various measures for
assessing economic burden of ADRD, synthesize the findings from recent studies regarding
costs of ADRD in the US population, highlighted major sources of variation in costs,
identified knowledge gaps, and briefly outlined directions for future research and
implications for policy and program planning.
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2. Literature search
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In this paper, we reviewed articles on direct and indirect costs of ADRD in the United States
that were published in English between January 2006 and February 2017. To identify
qualifying studies, we searched three scientific databases via EbscoHost (Medline,
PsycINFO, and Web of Science) and scanned bibliographies of relevant review papers and
identified articles. Search strings included different combination of the keywords ‘dementia,ʼ
‘alzheimer*ʼ together with ‘economic,ʼ ‘expenditure,ʼ and ‘cost.ʼ One example of such a
combination was (dementia OR alzheimer*) AND (‘economicʼ OR ‘expenditureʼ OR
‘costʼ). Cost studies that did not target adults with ADRD, or did not include cost data, were
excluded. We excluded conference abstracts, doctoral and master’s theses, and ‘gray’
literature. Of the 46 potentially relevant abstracts and citation indices scanned, 31 potentially
eligible papers were identified for closer review. A total of 17 published articles met our
eligibility criteria and were included in this review (Tables 1 and 2). Of these, nine studies
[5–13] were on individuals with AD diagnosis, four studies [16,19–21] were on individuals
with ADRD. These studies identified ADRD using International Classification of
Diseases-9th edition clinical modification (ICD9-CM) codes for AD, VD, FTD, LBD, and
unspecified dementias (senile dementia uncomplicated, senile dementia w/delusional or
depressive features, senile dementia w/delusional features, senile dementia w/depressive
features, dementia in conditions classified elsewhere, dementia in conditions classified
elsewhere without behavioral disturbance, or senility w/o psychosis and presenile dementia)
and four studies [14,15,17,18] were based on individuals with dementia identified using
cognitive screening measures.

3. Identification of ADRD
Author Manuscript
Author Manuscript

One of the challenges in deriving precise estimates of costs of ADRD is the difficulty of
identifying patients with ADRD. In the absence of specific biomarkers for differentiating the
various subtypes of dementia, diagnosis of ADRD has remained essentially a clinical
diagnosis based on patient’s cognitive and functional history, clinical examinations, and
neuropsychological testing. As illustrated in Table 3, studies have used varying criteria and
methods for defining ADRD. The most commonly used diagnostic criteria for identifying
dementia are those detailed in the Diagnostic and Statistical Manual of Mental Disorders
(DSM); these criteria were developed by the American Psychiatric Association and require
(1) a continued gradual decline in memory function and (2) cognitive deficits in one or more
domains which impair social and occupational functioning [23]. AD is often diagnosed
using the National Institute on Neurological and Communicative Disorders and Stroke and
the Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) criteria
originally proposed in 1984 [24]. These criteria require a gradual and continued decline in
two or more areas of cognition that is supported by clinical examination, neuroimaging tests,
and cognitive screening tests such as Mini-Mental State Examination, Clinical Dementia
Rating, Blessed Dementia Rating Scale, and other neuropsychological tests. Many registrybased studies that have assessed the economic costs of AD have identified patients using the
NINCDS-ADRDA criteria for ‘probable’ AD and/or the DSM-III-R or DSM-IV criteria
[5,18,23–25].
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Alternatively, studies using the Health Retirement Survey (HRS), a nationally representative
survey of adults aged 50 or older, determined probability of dementia with predictive
modeling [14,15]. In these studies, probable dementia was identified using in-home clinical
assessments on a sample of adults, and these data were then used to extrapolate ADRD
prevalence in the population. However, given that these estimates are based in part on
documented limitations in cognition and function, ADRD may be underestimated among
individuals with mild symptoms/early stage disease.

Author Manuscript

In studies using the Medicare Current Beneficiary Survey (MCBS), a survey of nationally
representative sample of beneficiaries enrolled in Medicare, ADRD has been determined
using any of the three criteria: (1) self or proxy reports, (2) medications, and (3) the
International Classification of Diseases-9th edition clinical modification (ICD9-CM) codes
for ADRD [21] (Table 3). In other investigations relying on Medicare [20], Medicaid
[16,26], and other commercial insurance claims databases [6,7], ADRD was likewise
identified using the ICD9-CM codes recorded in inpatient, outpatient, skilled nursing home,
and home health-care claims.

Author Manuscript

Limitations of most existing studies with respect to ADRD identification include lacking or
inadequate information on ADRD severity as well as under diagnosis or misdiagnosis of
ADRD leading to over or under estimation of costs. Claim-based studies use inpatient and
outpatient claims to identify ADRD and do not have high sensitivity and specificity in
identifying ADRD [27,28]. Therefore, there is potential to misclassify ADRD cases. In one
study comparing the Medicare costs estimates for patients with ADRD to the costs of
patients without ADRD, ADRD is identified in two different ways: one using Medicare
claims and the other using clinical examinations [28]. Researchers reported that using
Medicare claims resulted in substantial overestimation of the costs attributed to ADRD as
compared to using clinical examinations to identify patients with ADRD [28]. In this study,
using Medicare claims to identify ADRD was associated with a 110% increase in costs for
those with ADRD as compared to a 68% increase when using clinical examinations to
identify ADRD [28]. Similarly, a study using 5% Medicare claims data found that a
considerable number of Medicare beneficiaries with VD or Parkinson’s dementia were
misdiagnosed as AD, comprising almost 25% of reported AD cases [29]. Such misdiagnosis
resulted in an incremental annual Medicare expenditure of $9500–$14,000 among the
patients; this excess expenditure was largely eliminated after correcting for misdiagnoses
[29]. Research has also shown that the chronology of AD diagnosis has substantial impacts
on health-care costs. For example, patients who initially receive a diagnosis of cognitive
impairment other than AD and are later diagnosed with AD incur significantly higher healthcare costs as compared to those who receive AD as their initial diagnosis [30].

Author Manuscript

4. Economic burden of ADRD: direct medical, nonmedical, and indirect
costs
The economic burden of a disease is often assessed by measuring costs of the disease for
society or part of society. Costs of a disease are typically grouped into direct and indirect
costs. Direct medical costs of ADRD are associated with the use of resources for medical
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care including hospital visits, physician visits, emergency department visits, pharmacy, and
short-term skilled nursing facility care. Direct nonmedical costs include those associated,
paid formal home-health care, transportation costs to health-care providers and costs of
making necessary modifications to one’s diet, house, car, or related items. Indirect costs
include costs due to premature death or loss of productivity, as well as costs of informal
(unpaid) care.
4.1. Estimates and projections of national economic burden of ADRD

Author Manuscript

Estimates for the total direct medical costs of ADRD at the national level have been
calculated by multiplying per capita cost estimates by the expected prevalence of ADRD in
the population. For direct medical expenditures, the costs of care for prevalent ADRD in
year 2010 in the United States were estimated as $109 billion [14]. Due to the accelerated
aging of the population, this cost is projected to reach $259 billion by 2040, assuming that
the current prevalence of ADRD and per capita direct medical cost of ADRD remain stable
[14]. On the other hand, if recent declines in ADRD prevalence continue, estimated direct
costs of prevalent ADRD would increase to only $154 billion by 2040, a more modest, but
still substantial (70%) increase [31]. Thus, the broad variation in estimates of future direct
costs of ADRD in part reflects differential assumptions regarding projected ADRD
prevalence, cost of medical services for ADRD, and longevity of the population. As
illustrated in the section on per-capita direct medical costs, variations in per-capita direct
medical costs can also contribute to the variations in the national cost estimates.

Author Manuscript

In terms of indirect costs, the aggregate cost in 2010 for informal caregiving for ADRD in
the United States was estimated at $159 billion dollars and $215 billion dollars using the
forgone wage and replacement cost approach, respectively. This estimate exceeds the direct
cost estimate of $109 billion in 2010 [14]. Assuming that the prevalence of ADRD remains
constant at 2010 levels, these costs would increase to $379 billion and $511 billion,
respectively, by 2040 [14]. Alternatively, using the same approach to valuing caregiver time
but assuming a continued decline in ADRD prevalence, informal caregiving costs would
increase to $226 and $305 billion, respectively, by 2040 [31].
4.2. Per-capita direct health-care costs of ADRD

Author Manuscript

In the United States, direct health-care costs are borne by insurers (both private and public)
as well as by patients and their families. Currently, 68% of the total direct health-care costs
of ADRD are covered by Medicare, a federal insurance program, and Medicaid, a federally
subsidized insurance program administered by the states [2]. In 2015, Medicare spent an
estimated $226 billion and Medicaid paid an estimated $44 billion on total direct health-care
costs for individuals with ADRD [2]. The direct health-care costs can be further divided by
the type of service such as inpatient visit, outpatient visit, physician office visit, pharmacy,
emergency department, diagnostic and laboratory tests, long-term care, home care, and
hospice care. For individuals with ADRD, long-term or nursing home care costs are a
particularly critical component of total health-care costs.
The direct health-care costs of ADRD have typically been reported over variable time
periods. These include prevalence-based costs, post-diagnosis costs, lifetime costs, and end-
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of-life costs. As costs of chronic conditions may follow a U-shape curve, peaking during the
initial diagnosis and end-of-life periods, cost estimates may vary depending on at what stage
the costs were captured.
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4.2.1. Prevalence-based costs—The economic burden of ADRD has been measured
using a snapshot of costs in 1 year known as the prevalence-based cost approach. Under this
approach, costs are estimated for all individuals with ADRD in a given year (both incident
and prevalent cases); such estimates are often used for budgetary allocations and for policy
and program planning. In a study using HRS data, researchers reported that in 2010, the total
per capita annual direct health-care costs of dementia were $28,501 [14]. Using the Medical
Expenditures Panel Survey, community-dwelling adults over the age of 65 with ADRD had
44% higher total health-care expenditures compared to patients without ADRD [19]. As can
be seen from Table 1, there is a considerable variation in these costs based on the data
sources, setting, and stage of ADRD.
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4.2.2. Costs around the time of ADRD diagnosis—Nearly 30% of ADRD diagnoses
occur during hospitalization for another serious condition such as cardiovascular disease,
cerebrovascular diseases pneumonia, kidney disease, or infection [20]. Therefore, studies
that focus on the immediate period after diagnosis can show higher costs (Table 1).
Interestingly, studies assessing the direct medical costs around the time of ADRD diagnosis
have shown that direct medical expenditures among individuals with ADRD were already
significantly higher in the pre-diagnosis period than their non-ADRD counterparts perhaps
due to diagnostic workup, early manifestations of cognitive impairment, and higher
comorbidity burden (Table 1). In a recent study using 5% sample of Medicare claims, Lin et
al. found that Medicare expenditures were 42% higher in the ADRD cohort in the 1-year
pre-diagnosis period as compared to the matched non-ADRD cohort.

Author Manuscript

Following the diagnosis of ADRD, the Medicare expenditures increased 3 times within 1year and by 1.7 times by 2 years [30]. Similar pattern was observed in another study using
Medicare Advantage Prescription Drug plan dataset. This study revealed that during the year
prior to diagnosis of ADRD, total medical expenditures were 44% higher, 1 year after
diagnosis, the total medical expenditures were 2 times higher, and 2 years after diagnosis,
the total medical expenditures were 1.7 times higher in the AD versus non-AD cohort [12].
In addition, the perceptions of physicians, patients, and family members regarding ADRD
may also affect health-care utilization following an ADRD diagnosis. Therefore, in a
prospective multicenter study, researchers followed community dwelling Medicare
beneficiaries at multiple centers in the northern Manhattan area of New York and clinically
examined them to diagnose incident AD; however, both patients and their providers were
blinded to the diagnosis of AD [18]. Nonetheless, Medicare expenditures were 65% higher
in those diagnosed with AD than in those not diagnosed in the 2 years preceding diagnosis.
After diagnosis, Medicare expenditures doubled in the AD cohort, whereas it only increased
by 43% in the non-AD cohort.
4.2.3. End-of-life costs—Table 1 also presents end-of-life costs associated with ADRD.
In a study using a prospective cohort of nursing home residents with advanced AD, Goldfeld
et al. reported that the average total Medicare expenditures increased by 65% in the year
Expert Rev Pharmacoecon Outcomes Res. Author manuscript; available in PMC 2018 April 01.
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prior to death, with costs progressively increasing as death approached ($1061: 365–271
days before death; $1605: 270–121 days before death; $2297: 120–91 days before death,
and $3877: 90–0 days before death) [9]. The major drivers for end-of-life Medicare costs
were hospitalizations (30.2%) and hospice care (45.6%) [9]. One retrospective cohort study
using the HRS data assessed Medicare and Medicaid costs among patients with versus
without dementia in the 5 years prior to death [15]. While there was no significant difference
in the adjusted total Medicare spending in the dementia versus non-dementia group, average
Medicaid spending was nearly 8 times higher in those with versus without ADRD [15].
Medicaid is the primary payer for long-term care for Medicaid eligible patients. Many
patients who are not initially eligible for Medicaid may, after ‘spending down’ their assets,
ultimately transition to Medicaid-supported long-term care. In contrast, Medicare does not
support nursing home care, the major driver of end-of-life costs in adults with ADRD. Thus,
it is not surprising that excess Medicare expenditures associated with ADRD are lower than
excess Medicaid costs.
4.2.4. Life-time costs—Individuals with ADRD experience gradual declining health with
an average life-expectancy of 8–10 years [32]. Cost estimates of ADRD may depend on the
time during which costs are captured; therefore, it is important to estimate life-costs of
ADRD [21]. As can be seen from Table 1, in a cohort-based simulation study assessed the
lifetime costs of AD using the MCBS data. This study estimated the average lifetime
Medicare expenditures using an estimated 5.1 year duration of dementia and found that the
average lifetime Medicare expenditures was 13% higher ($101,810 vs. $89,835) and the
average lifetime Medicaid expenditures was 69% higher ($27,028 vs. $15,955) per AD
patient as compared to non-AD control group [21]. Not surprisingly, it was also reported that
lifetime costs could be lowered with shorter duration of AD [21].

Author Manuscript

4.3. Type of direct health-care costs specific to ADRD

Author Manuscript

4.3.1. Formal home-health care costs—The unique characteristics of ADRD influence
the drivers of direct health-care costs for ADRD. Due to the progressive decline in cognitive
and functional status, many older patients with ADRD need home–health care and may
spend their last years of life in long-term care facilities (Table 1). The annual number of paid
home-health visits in the first year following ADRD diagnosis averaged 30 versus 13 among
those without an ADRD diagnosis [20]. As the disease progresses, use of formal homehealth care use also increases. For example, in a prospective cohort study of elders with
early stage AD at baseline, the percentage of patients receiving paid home health increased
from 9.9% at the time of diagnosis to 34.5% by 4 years. The incremental total costs for paid
home care in 2010 was $5678, accounting for 20% of the incremental direct costs associated
with ADRD [14]. In one prospective study of Medicare beneficiaries, it was observed that
excess costs of ADRD were largely due to home-health care, skilled nursing care, and
durable medical equipment [18].
4.3.2. Nursing home costs—On average, individuals with mild-to-moderate ADRD
aged between 70 and 80 years spend 3 years in a nursing home while those with severe
ADRD spend 4 years in nursing home [33]. Therefore, a substantial portion of the direct
costs associated with ADRD is for nursing home stays. In the United States, almost 75% of
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the oldest adults with ADRD (≥80 years) are nursing home residents as compared to only
4% of those without ADRD [33]. Therefore, it is not surprising that nursing home costs
account for a major portion of the incremental total direct expenditures associated with
ADRD [14]. For example, using HRS, a study reported that nursing home care costs
accounted for 49% of the total direct medical costs of ADRD [14].
In the United States, Medicare does not cover long-term care stays; therefore, many ADRD
patients rely on Medicaid to cover their long-term care expenditures. For example, in a
retrospective cohort study of older Indiana Medicaid beneficiaries, 93% of the incremental
Medicaid expenditures associated with ADRD were for nursing home stays [16]. Many
ADRD patients required skilled nursing home care. It has been reported that during the year
after diagnosis, skilled nursing home care costs were 9 times higher ($6755 vs. $727) 1 year
after diagnosis in the ADRD cohort compared to no ADRD cohort [30].

Author Manuscript

4.4. Out-of-pocket spending by patients and their families

Author Manuscript

Although Medicare provides health-care coverage for most of the elderly in the United
States, many elderly and their families pay for medical care out of their pockets. Out-ofpocket spending includes spending on health insurance premiums, deductibles, coinsurance,
and copayments for medical care and prescription drugs; certain services or equipment only
partially covered or not covered by insurance; non-prescription medications; transportation
to health-care providers; and uncovered structural or lifestyle modifications. According to
the Global Health Observatory (GHO) data, out-of-pocket health-care expenditures by
patients and/or their families comprised 45% of total health-care expenditures in 2014 [34].
Among Medicare beneficiaries, health insurance premiums account for 42% of the total outof-pocket spending, with payments toward cost-sharing and non-covered services and goods
accounting for the remaining 58% [35]. It is important to assess the magnitude of out-ofpocket expenditures because high out-of-pocket expenditures can also lead to worse health
outcomes because of access issues. For example, individuals with high out-of-pocket costs
may be more likely to stop taking their medications [36], less likely to use preventive care,
and less likely to use outpatient services for their health care [37,38].

Author Manuscript

Estimation of out-of-pocket health-care expenditures burden is especially important for
those with chronic conditions such as ADRD because these individuals may require longterm medical care, residential services, and prescription drugs. Despite its importance, only
few studies have evaluated out-of-pocket spending in the US population [13–15,39]. In an
article not specific to ADRD, Hurd et al. examined average out-of-pocket spending among a
nationally representative sample of older adults (HRS) with dementia [14]. In this study, outof-pocket spending included costs borne by the patient and the families for the following
services: nursing home, hospital, medical visits, outpatient surgery, home-health care,
rehabilitation, prescription drugs, and dental services. This study found that adults with
dementia spent on the average $6838 out-of-pocket, an amount that was only slightly
attenuated by adjustment for demographic factors and coexisting conditions (adjusted mean
= $6194, 95% CI $4522, $7866). This figure may represent an underestimate because outof-pocket spending estimates did not include health insurance premiums and the study did
not focus on those with ADRD [14]. Using data from the MCBS, it was estimated that
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patients with ADRD and their families spent an average of $10,495 out-of-pocket for ADRD
care, with those residing in long-term care facilities or assisted living facilities spending 6
times as much as community dwelling patients with ADRD [2]. In another HRS study of
decedents with likely/probable dementia, mean out-of-pocket costs for last 5 years of life
totaled $61,522 for those with dementia and these individuals spent nearly 32% of their
expenditures out-of-pocket [15]. Researchers using data from the nationally representative
Aging, Demographics, and Memory Study found that individuals with dementia had more
than 3 times annual out-of-pocket spending relative to those with normal cognition [39].
None of these studies examined out-of-pocket burden as measured by the percent of income
spent on medical and nonmedical care.

Author Manuscript

As stated above, as many as three quarters of all patients with ADRD will require care in a
long-term care facility [40]. Therefore, it is not surprising that individuals with ADRD spent
a major proportion of their out-of-pocket costs on long-term care facilities [35]. Long-term
facility costs account for much of the cost-sharing among Medicare beneficiaries who also
qualified for Medicaid [41], suggesting that even with dual coverage of Medicare and
Medicaid, individuals with ADRD face a significant financial burden.
High out-of-pocket expenditures can be borne not only by ADRD patients but also by their
caregivers. These expenditures may include travel, medical supplies, food, and groceries.
According to the Usage and Attitudes Family Caregiver Survey, nearly 50% of caregivers
spent over $5000 annually [42]. Such expenditures can exact a toll on the caregivers by
reducing their ability to pay for food, housing, health-care, and other basic needs and thus
lead to significant declines in caregiver health and well-being [10,11,43].
4.5. Indirect costs

Author Manuscript

As stated above, another component of ADRD costs is the indirect costs that include costs
due to loss of productivity as well as costs of informal (unpaid) care. Typically, indirect costs
exclude costs specific to disease treatment [44]. In general, valuation of the productivity
losses for elderly and specifically for patients with ADRD are scarce. As friends and family
members provide nearly 75% of all caregiving for patients with ADRD [10,45], productivity
loss is not limited to patients with ADRD but also affects informal caregivers who provide
care for patients with ADRD [5,8,17]. As summarized in Table 2, in an epidemiological
study using the HRS data, Friedman et al. reported that older adults with probable ADRD
received 171 h of informal care per month versus 66 h for those without ADRD [46].
However, medical care provided by unpaid caregivers is not always included in costs
estimations for ADRD.

Author Manuscript

The informal cost of care for ADRD is usually measured by valuing the time lost due to
unpaid caregiving using the human capital approach. Initially, informal caregiving time is
assessed in terms of caregiving hours per day or per week. Caregiving time is then valued in
terms of either the replacement cost of hiring paid formal care or the opportunity cost due to
lost wages (foregone wages). The former is measured by monetizing caregiving hours based
on market wages paid to formal (paid) caregivers [13,14]; the latter is measured by valuing
caregiving time in terms of the caregiver’s expected market wage based on the caregiver’s
age, education, previous income, or occupation [5,8,14,15,17]. Details on data source,
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informal cost estimation approach, wage estimates, and per capita cost estimates can be seen
in Table 2.
Estimates of informal caregiving may vary depending on whether the replacement costs or
the foregone wage approach is used. Using the same cohort of patients, average adjusted
annual informal caregiving was valued at $13,188 (2010 USD) using the replacement costs
approach and $27,789 (2010 USD) using the foregone wages approach by Hurd and
colleagues in an analysis of the HRS data [14]. The foregone wage approach has been used
in other studies to estimate informal caregiver costs (see Table 2) [5,8,15,17].
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The estimate of indirect costs due to ADRD requires the consideration of factors other than
productivity losses. Indirect ADRD costs need to include caregiver’s health-care resource
utilization and health-care costs. It has been reported that members of households with AD
patients were estimated to have significantly greater total annual medical, pharmacy, and
total health-care costs than did those without AD patients [11]. For all caregivers of ADRD
patients, average annual medical care costs have also been shown to rise as care recipient’s
condition progressed [10].

5. Expert commentary
5.1. Key findings

Author Manuscript

A consistent finding of all studies comparing individuals with and without ADRD is that the
average medical, nonmedical, and indirect costs of individuals with ADRD are higher than
those of individuals without ADRD [6,7,12,15,18–21], despite the differences in source of
payment (Medicare, Medicaid, out-of-pocket), time period (lifetime vs. annual) and study
population (e.g. decedents vs. all adults, AD vs. all forms of dementia), and stage of disease.
Because of the long duration and the progressive cognitive and functional impairment
characterizing ADRD, nursing home and home health-care services accounted for a
substantial portion of the direct costs associated with ADRD. Nursing home stays, home
health-care services, and informal caregiving accounted for more than three-fourth of the
total costs associated with ADRD [14]. For community-dwelling individuals with ADRD,
the indirect costs of ADRD far exceeded the direct costs of ADRD due to the high need for
formal and informal caregiver services in these vulnerable populations [14,15]. In the United
States, the combined direct and indirect costs of ADRD is higher than those of other serious
chronic illnesses, including stroke, diabetes, heart disease, hypertension, lung disease,
cancer, psychiatric problems, and arthritis in the US population [15].
5.2. Major sources of variation in costs

Author Manuscript

One important source of variation in the cost estimates stems from the differences in the
method of determining ADRD across studies. Studies using administrative claims data such
as Medicaid, Medicare, MarketScan, and PharMetrics have identified AD/ADRD based on
diagnosed ADRD, whereas studies using survey data such as the HRS have assessed ADRD
based on cognitive screening measures and registry-based studies have used clinical
examinations to determine AD/ADRD. Studies that use claims data to identify ADRD at a
particular point in time need to be particularly cautious in defining AD, because both
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underreporting (mild cases) and misdiagnosis are common, potentially leading to inaccurate
estimates of care costs for individuals with AD [28,29]. In addition, because the onset of AD
is insidious, cognitive decline is typically gradual, and compensatory behaviors can mask
early symptoms, capturing ‘true’ incident cases of AD can be challenging. The higher
estimates of medical expenditures generated using claims based versus registry data likely
reflect differences in stage of disease at diagnosis; while registries capture incident ADRD,
claims data are more likely to reflect those with more advanced disease [18,20].

Author Manuscript

Other sources of variations in the cost estimates of studies are due to the determination of
costs using approaches such as prevalence-based costs [14] versus incidence-based costs
[20]. Studies that assessed annual costs of ADRD after incidence usually have higher
estimates as compared to studies that have assessed costs using prevalence based approach.
Other sources of variations in costs are due to the differences in the population setting
(community vs. nursing home) and differences in the source of pay (Medicare, Medicaid,
out-of-pocket).

6. Five-year view
6.1. Knowledge gaps and implications for future research
Direct nonmedical costs play a particularly important role in ADRD because as the disease
progresses, home-safety modifications, safety services, personal care, adult day care, and
full-time residential services are typically required [8,14]. Because studies generally do not
include many of these costs, the cost burden of ADRD may be underestimated.

Author Manuscript

There remains a significant knowledge gap regarding estimation of indirect costs. Studies
assessing the indirect costs of ADRD have primarily focused on the productivity loss or
replacement cost of informal caregivers. However, caregiver burden is multidimensional
[47]. Importantly, the chronic stressors associated with caregiving for ADRD patients can
have significant adverse effects on caregiver health, increasing risk for depression, anxiety,
hypertension, cardiovascular disease, dementia, and ultimately, mortality [48–51].
Therefore, to better capture the economic burden of ADRD, future studies need to measure
loss in caregiver productivity, caregivers’ health, absenteeism, and employment. This
information can help inform the development of programs and policies to more effectively
address the burden of informal caregivers who provide care for ADRD patients.

Author Manuscript

Many studies have used insurance claims to estimate costs of ADRD. Claim-based databases
are important because policy makers and payers also have developed new payment models
(shared savings), performance evaluation (Centers for Medicare and Medicaid Services’s
Star Rating System, National Quality Forum performance measures), payment reduction
(e.g. 30-day readmissions for certain chronic conditions), and other policies to ensure highquality patient-centered care. With these shifts, administrative claims data have become vital
to population health management. As most of the direct home health-care costs in the United
States are borne by Medicare and most of the long-term care costs are borne by Medicaid,
studies using only Medicare, Medicaid, or private insurance claims databases may
underestimate the direct medical costs of care for ADRD.
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Therefore, to improve economic analysis of the direct and indirect costs of ADRD, efforts
should be directed toward linking various registries of AD/ADRD and surveys with multiple
administrative claims datasets from all payers. In this context, the all payer claims database
(APCD) initiatives that are being implemented can offer great value for individuals covered
by multiple health-care plans because of the industry-wide coding standards of health-care
encounters. These databases will assist practitioners in patient care by providing a ‘360degree’ view of patients’ health care and ‘actionable intelligence’ that can offer specific
guidance for improving chronic disease management. Indeed, use of health analytics
involving large databases has been shown to bring about improvements such as increased
adherence to guideline-based care, enhanced surveillance and monitoring, and decreased
medication errors [52]. As of January 2016, 18 states have an APCD to help policy decision
makers with cost containment and quality improvement strategies [53]. Unfortunately,
establishment of APCDs has been met with resistance, and in 2015, the US Supreme Court
ruled that self-insured group health plans are not required to comply with ACPD data
requests [54]. Despite this setback, APCD implementation may not be significantly affected
since many states have already received buy-in from these self-insured group health plans
[55].
Additionally, long-term, prospective studies that track ADRD costs over time are needed
because cost estimates can differ significantly based on ADRD severity. By helping to
delineate the components, trajectories, and major drivers of costs and burden associated with
ADRD from disease onset to end-of-life, findings from these studies will aid in program
planning and help identify optimal timing for intervention.
6.2. Potential impact of emerging technology and treatment on ADRD burden
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With the advances in neuroimaging technologies including volumetric magnetic resonance
imaging, single-photon emission computed tomography, positron emission tomography
imaging, cerebrospinal fluid beta, tau metabolites, and other serum markers, it may soon be
possible to detect the ADRD at a prodromal or preclinical stage before the signs of the first
clinical symptoms [56]. A recent predictive economic model has shown that the use of a
neuroimaging technique for detection of early indicators of AD pathophysiology (with 90%
sensitivity and specificity) and a disease modifying treatment that retards AD progression by
50% would reduce the lifetime risk of AD in elderly adults from 10.5% to 5.7% [57].
Technological innovations for ADRD caregivers may reduce the caregiver burden. For
example, intelligent assistive devices currently under development such as cognitive aids,
environmental sensors, video and audio technologies to support daily life activities and
monitor the safety of individuals with dementia have the potential to significantly reduce the
burden of informal and formal caregiving for dementia [58].

7. Implications for future policy and program planning
The development and implementation of high impact policy and programs to reduce the
escalating economic burden of ADRD requires a comprehensive understanding of the direct
and indirect costs of ADRD throughout the disease trajectory. As long-term institutionalized
care accounts for a significant portion of the federal and state spending on ADRD, policies
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should be implemented to shift long-term care from institutional settings to home- and
community-based settings [59]. This would necessitate implementation of new home- and
community-based services and inclusion of such services in state Medicaid plans, as well as
expansion of financial compensation programs for caregivers of patients with ADRD.
Additionally, policy makers should facilitate the adoption of intelligent assistive devices and
other technology-based services to reduce the burden on caregivers.
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Key issues
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•

Identifying patients with ADRD is very challenging. Due to differences in
diagnostic criteria and application, ascertainment and categorization of
ADRD may vary across studies, leading to potential misclassification and
inaccurate cost estimates.

•

Despite the definitional differences, studies comparing patients with and
without ADRD have consistently reported that the average medical, nonmedical, and indirect costs of individuals with ADRD were higher than those
without ADRD.

•

Nursing home costs and formal home-healthcare costs are the major
contributors of the total direct costs of ADRD.

•

Out-of-pocket expenditures on medical and non-medical services also impose
a significant burden on patients and their caregivers. Yet there is no precise
estimate of out-of-pocket expenditures burden as measured by income spent
out-of-pocket.

•

The overall economic burden of ADRD may be underestimated because many
non-trivial components of costs such as direct non-medical costs and indirect
costs are not included in the cost estimates.

Author Manuscript
Author Manuscript
Expert Rev Pharmacoecon Outcomes Res. Author manuscript; available in PMC 2018 April 01.

Author Manuscript

Author Manuscript

Author Manuscript
2 years pre- and
post-diagnosis

2 years pre- and
post-diagnosis

5 years before
death

Zhu, Cosentino
et al. [18]

Kelley, McGarry
et al. [15]

1 year

Deb,
Sambamoorthi et
al. [19]

Lin, Zhong et al.
[20]

Follow-up time

Study

Expert Rev Pharmacoecon Outcomes Res. Author manuscript; available in PMC 2018 April 01.
HRS

Community dwelling Medicare
beneficiaries in northern Manhattan

5% sample of Medicare claims

MEPS

Data source

Dementia

Dementia

ADRD

ADRD

ADRD/AD/Dementia

Retrospective

Prospective multicenter

Retrospective

Retrospective

Study design

Yes

Yes

Yes

Yes

Control group

In 2010 US dollars:
Total costs in the last 5 years: (dementia
vs. no dementia)
Medicare costs: $86,430 vs. $98,326
Medicaid costs: $35,346 vs. $4552

In 2012 US dollars (author’s calculation a):
Excess Medicare costs per quarter:
2 years pre-diagnosis: $1003 (ref = no
dementia)
2 years post-diagnosis: $1895 (ref =
pre-diagnosis)
In 2015 US dollars:
Excess Medicare costs per quarter:
2 years pre-diagnosis: $1085 (ref = no
dementia)
2 years post-diagnosis: $2049 (ref =
pre-diagnosis)

In 2014 US dollars:
Total Medicare costs per year: (AD vs.
non-AD)
2 years pre-diagnosis: $10,533 vs.
$10,102
1 year pre-diagnosis: $15,091 vs.
$10,662
1 year post-diagnosis: $27,126 vs.
$9274
2 years post-diagnosis: $17,257 vs.
$9,930
In 2015 US dollars (author’s calculation a):
Total Medicare costs per year: (AD vs.
non-AD)
2 years pre-diagnosis: $10,791 vs.
$10,349
1 year pre-diagnosis: $15,460 vs.
$10,923
1 year post-diagnosis: $27,790 vs.
$9501
2 years post-diagnosis: $17,679 vs.
$10,173

In 2013 US dollars:
Total health-care costs per year: (ADRD
vs. non-ADRD)
$14,508 vs. $10,096
In 2015 US dollars (author’s calculationa):
Total health-care costs per year: (ADRD
vs. non-ADRD)
$15,216 vs. $10,588

Adjusted per capita cost estimates

Per capita direct cost estimates of Alzheimer’s diseases and related dementias (ADRD) used in cost of illness studies in the United States.
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Lifetime cost (5year duration)
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Yang, Zhang et
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Dedhiya et al.
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Indiana Medicaid

Medicare Current Beneficiary Survey

MAPD plan members

HRS

Data source

ADRD

ADRD

AD

Dementia

ADRD/AD/Dementia

Retrospective

Cohort-based simulation

Retrospective

Retrospective

Study design
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Follow-up time

Yes

Yes

Yes

Yes

Control group

In 2004 US dollars:
Incremental Medicaid costs: $9829
In 2015 US dollars (author’s calculation a):
Incremental Medicaid costs: $14,567

In 2005 US dollars:
Total lifetime costs (ADRD vs. nonADRD):
Medicare: $101,810 vs. $89,835
Medicaid: $27,028 vs. $15,955
In 2015 US dollars (author’s calculation a):
Total lifetime costs (ADRD vs. nonADRD):
Medicare: $143,982 vs. $127,047
Medicaid: $38,224 vs. $22,564

In 2011 US dollars:
Excess annual total health-care costs: (ref
= non-AD)
1 year pre-diagnosis: $2331
1 year post-diagnosis: $9333
2 years post-diagnosis: $5761
In 2015 US dollars (author’s calculation a):
Excess annual total health-care costs: (ref
= non-AD)
1 year pre-diagnosis: $2619
1 year post-diagnosis: $10,486
2 years post-diagnosis: $6473

In 2010 US dollars:
Total annual costs attributable to dementia:
Direct medical costs: $28,501
Medicare costs: $2752
Out-of-pocket costs: $6194
Nursing home costs: $13,876
Formal Homecare costs: $5678
In 2015 US dollars (author’s calculation a):
Total annual costs attributable to dementia:
Direct medical costs: $33,004
Medicare costs: $3187
Out-of-pocket costs: $7173
Nursing home costs: $16,086
Formal homecare costs: $6575

Out-of-pocket costs: $61,522 vs.
$34,068
In 2015 US dollars (author’s calculation a):
Total costs in the last 5 years: (dementia
vs. no dementia)
Medicare costs: $100,084 vs. $113,860
Medicaid costs: $40,930 vs. $5271
Out-of-pocket costs: $71,241 vs.
$39,450

Adjusted per capita cost estimates
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1 year from first
diagnosis of AD

Joyce, Zhao et
al. [6]

PharMetrics Patient-Centric Database

MarketScan Medicare Supplemental

CASCADE study

AD

AD

AD

ADRD/AD/Dementia

Retrospective

Retrospective

Prospective cohort

Study design

Yes

Yes

No

Control group

In 2003 US dollars:
Total health-care costs (AD vs. non-AD):
$21,150 vs. $4053
In 2015 US dollars (author’s calculation a):
Total health-care costs (AD vs. non-AD):
$32,912 vs. $6307

In 2003 US dollars:
Total health-care costs (AD vs. non-AD):
$13,936 vs. $10,369
In 2015 US dollars (author’s calculation a):
Total health-care costs (AD vs. non-AD):
$21,686 vs. $16,135

In 2007 US dollars:
Total Medicare costs among NH residents:
0–90 days before death = $3877
91–120 days before death = $2297
121–270 days before death = $1605
271–365 days before death = $1061
In 2015 US dollars (author’s calculation a):
Total Medicare costs among NH residents:
0–90 days before death = $4999
91–120 days before death = $2962
121–270 days before death = $2069
271–365 days before death = $1368

Adjusted per capita cost estimates

Authors converted costs to 2015 US dollars using the Consumer Price Index for Medical Care Services [22]. MEPS: Medical Expenditure Panel Survey; HRS: Health and Retirement Study; MAPD:
Medicare Advantage Prescription Drug; CASCADE: Choices, Attitudes, and Strategies for Care of Advanced Dementia at the End-of-Life.

a

1 year

Kuo, Zhao et al.
[7]

0–90, 91–120,
121–270, 271–
365 days before
death

Author Manuscript

Goldfeld,
Stevenson et al.
[9]

Author Manuscript
Data source

Author Manuscript

Follow-up time

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript
Health and
Retirement Study

Predictors 2 Study

Medicare Current
Beneficiary Survey

Cache County
Dementia
Progression Study

Humana Medicare
Advantage
Prescription Drug
plan

Health and
Retirement Study

Zhu, Scarmeas et al
[10]

Yang, Levey [13]

Rattinger et al. [17]

Suehs, Shah et al.
[11]

Hurd, Martorell et
al. [14]

Data source

Kelley, McGarry
et.al. [15]

Study
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Dementia

AD

Dementia

AD

AD

Dementia

ADRD/AD/Dementia

Retrospective

Retrospective

Retrospective

Retrospective

Retrospective

Retrospective

Study design

Forgone wage and
replacement cost

Personal medical costs
of household members

Foregone wage

Replacement cost

Personal medical costs

Foregone wage

Approach used to
estimate caregiver cost

Average wages for
persons with similar
demographic

–

Utah median hourly
wage as reported in the
US Bureau of Labor’s
Occupational
Employment Statistics

Used the replacement
cost inputs from Hurd
et al (2013)

–

State-average costs of
home health-care
services

Wage used to
estimate value
caregiver time

In 2010 US dollars:
Average annual costs of informal caregiving time:
Foregone wage approach: $13,188

In 2011 US dollars:
Annual health-care costs for household members
(AD vs non-AD): $7168 vs. $6301 In 2015 US
dollars (authors’ calculation a):
Annual health-care costs for household members
(AD vs non-AD): $8054 vs. $7079

In 2012 US dollars:
Average daily costs of informal dementia care at
start of study observationb: $40.07
In 2015 US dollars (authors’ calculation a):
Average daily costs of informal dementia care at
start of study observationb: $41.37

In 2013 US dollars:
Lifetime informal care costs:
Female family member of a male AD patient:
$54,956
Male family member of a female AD patient:
$8659 In 2015 US dollars (authors’ calculation a):
Lifetime informal care costs:
Female family member of a male AD patient:
$57,639
Male family member of a female AD patient:
$9082

In 2010 US dollars:
Total health-care costs of caregivers:
Year before baseline: $2585
Average across entire study period: $3068 In
2015 US dollars (authors’ calculation a):
Total health-care costs of caregivers:
Year before baseline: $2993
Average across entire study period: $3553

In 2010 US dollars:
Five-year informal care costs (dementia vs. nondementia):
$83,022 vs. $38,272 In 2015 US dollars (authors’
calculationa):
Five-year informal care costs (dementia vs. non
dementia):
$90,241 vs. $41,600

Per capita indirect cost estimates (adjusted unless
otherwise specified)

Per capita indirect cost estimates of Alzheimer’s diseases and related dementias (ADRD) used in cost of illness studies in the United States.

Author Manuscript

Table 2
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AD

Retrospective

Retrospective

Forgone wage

Forgone wage

Baseline severity of AD in informal care users, as assessed with Mini-Mental State Exam was 21.7.

Baseline severity of ADRD in informal care users, as assessed with Mini-Mental State Exam was 20.7.

b

c

Predictors Study

Zhu, Scarmeas et al.
[5]

AD

Authors converted costs to 2015 US dollars using the Consumer Price Index for Medical Care Services [22].

a

Predictors Study

Zhu, Scarmeas et al.
[8]

Study design

ADRD/AD/Dementia

Author Manuscript
Data source

Author Manuscript

Study

Author Manuscript
National average
hourly earnings for all
private industries

National average
hourly earnings for all
private industries

characteristics; and
average hourly rates
charged by home
health agencies in the
respondent’s state of
residence

Wage used to
estimate value
caregiver time

In 2004 US dollars:
Average annual informal care cost:
Unadjusted cost: $25,381 In 2015 US dollars
(authors’ calculationa):
Average annual informal care cost:
Unadjusted cost: $31,846

In 2004 US dollars:
Average annual costs of informal care:
Among users at baselineb: $20,590
Among users in year 4: $43,031 In 2015 US
dollars (authors’ calculation a):
Average annual costs of informal care:
Among users in baselinec: $25,835
Among users in year 4: $53,992

Replacement cost approach: $27,789 In 2015 US
dollars (authors’ calculation a):
Average annual costs of informal caregiving time:
Foregone wage approach: $14,335
Replacement cost approach: $32,179

Per capita indirect cost estimates (adjusted unless
otherwise specified)

Author Manuscript

Approach used to
estimate caregiver cost
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Table 3

Author Manuscript

Diagnostic definitions of Alzheimer’s diseases and related dementias used in cost of illness studies in the
United States.

Author Manuscript
Author Manuscript
Author Manuscript

Studies

Source

AD/ADRD/Dementia

Diagnostic definitions

Zhu, Scarmeas et
al. [5], Zhu,
Torgan et al. [8],
Zhu, Scarmeas et
al. [10]

Predictors Study

AD

Clinician-based diagnosis of:
(1) Primary degenerative AD based on DSM-IIIR criteria,
(2) Probable AD based on NINCDS-ADRDA
criteria, and
(3) Modified MMSE score of 30 or greater

Zhu, Cosentino et
al. [18]

Washington Heights-Inwood Columbia
Aging Project

AD

Clinician-based diagnosis of:
(1) Dementia based on DSM-IV criteria
(2) Probable AD based on NINCDS-ADRDA
criteria

Goldfeld,
Stevenson et al.
[9]

CASCADE study

Dementia

Clinician-based diagnosis of:
(1) Cognitive Performance Score equal to 5 or 6,
(2) Cognitive impairment due to dementia (any
type),
(3) Global Deterioration
(4) Scale score of 7 ascertained by nurse
interview, and
(5) Length of NH stay >30 days

Murman, Eye et
al. [25]

Neurology and geriatric medicine
practices in the state of Michigan, USA

AD

Clinician-based diagnosis of:
(1) Probable AD based on the NINCDS-ADRDA
criteria

Yang, Zhang et al.
[21], Yang and
Levey [13]

MCBS

AD

Based on
(1) Self or proxy reported diagnosis of ADRD,
(2) ICD-9-CM codes of 290 or 331.0, and
(3) Self or proxy reported prescriptions for
prescription for drugs including donepezil,
rivastigmine, galantamine, and memantine

Hurd, Martorell et
al. [14], Kelley,
McGarry et al.
[15]

Health and Retirement Study

Dementia

(1) Probable dementia was determined based on
an algorithm using multiple cognitive measures

Joyce, Zhao et al.
[6]

PharMetrics Patient-Centric Database

AD

At least one claim with a diagnosis of AD (ICD.
9.CM 331.0)

Kuo, Zhao et al.
[7]

MarketScan Medicare Supplemental and
Coordination of Benefits Database

AD

(1) At least one claim with a diagnosis of AD
(ICD.9.CM 331.0) and/or
(2) At least one pharmacy claims for tacrine,
donepezil, galantamine, rivastigmine, or memantine

Bharmal, Dedhiya
et al. [16]

Medicaid claims

Dementia

At least one claim with any dementia-specific
ICD-9 code (046.1, 290.0, 290.1x–290.4x, 291.2,
294.1x, 331.0, 331.1x, 331.2, or 331.82)

Gilligan, Malone
et al. [26]

Medicaid claims

AD

At least one claim with ICD-9 code of 331.0 in any
section of the inpatient, long-term care, or
outpatient Medicaid claim files

Suehs, Davis et al.
[12], Suehs, Shah
et al. [11]

Medicare Advantage Prescription Drug

AD

At least one claim with a diagnosis of AD (ICD.
9.CM 331.0)

Lin, Zhong et al.
[20]

5% Medicare sample–claims

ADRD

ICD-9-CM codes of 331.0, 331.11, 331.19, 331.2,
331.7, 290.0, 290.10, 290.11, 290.12, 290.13,
290.20, 290.21, 290.3, 290.40, 290.41, 290.42,
290.43, 294.0, 294.10, 294.11, 294.20, 294.21,
294.8, 797

DSM: Diagnostic and Statistical Manual of Mental Disorders; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical
Modification; MMSE: Mini-Mental State Examination; NH: Nursing Home; NINCDS-ADRDA: National Institute of Neurological,
Communicative Disorders and Stroke–Alzheimer Disease and Related Disorders Association; MCBS: Medicare Current Beneficiary Survey.
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